This New CEO Hits the Ground Running

Today, Fool.com healthcare bureau chief Brenton Flynn looks at AstraZeneca's brand-new CEO's announcement that the company is suspending share repurchases effective immediately. Given that AstraZeneca is facing a major patent cliff on the horizon, this is likely a wise decision. It will need to keep that powder dry in the event that they have to perform an acquisition.

There have been whispers that Forest Laboratories is the most likely target. While the two certainly have synergies, there are risks as well, particularly differences across the companies' R&D structure. 

When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2042112, ~/Articles/ArticleHandler.aspx, 4/16/2014 6:47:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASD 4,086.23 52.06 1.29%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/16/2014 11:55 AM
AZN $3755.21 Up +32.21 +0.87%
AstraZeneca CAPS Rating: No stars
FRX $90.29 Up +1.95 +2.21%
Forest Laboratorie… CAPS Rating: ****
GSK $52.82 Up +0.50 +0.96%
GlaxoSmithKline CAPS Rating: ***
RHHBY $36.17 Up +0.03 +0.08%
Roche Holding Ltd.… CAPS Rating: ****

Advertisement